Please wait while the formulary information is being retrieved.
NULIBRY (fosdenopterin hydrobromide)
- molybdenum cofactor deficiency type A
9.5 mg intravenous solution
- Infuse 0.9 mg/kg by intravenous route once daily at a rate of 1.5 ml/min
Default screening record
- Infuse 0.9 mg/kg by intravenous route once daily at a rate of 1.5 ml/min
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
NULIBRY (fosdenopterin hydrobromide)
- molybdenum cofactor deficiency type A
- Bacteremia
- Pneumonia
- Acute bacterial otitis media
- Cough
- Diarrhea
- Fever
- Gastroenteritis
- Sneezing
- Treatment site sequelae
- Upper respiratory infection
- Viral infection
- Vomiting
More Frequent
Severe
Less Severe
- Influenza
- Lower respiratory infection
- Seizure disorder
- Acute abdominal pain
- Agitation
- Anemia
- Maculopapular rash
- Pain in oropharynx
- Periorbital edema
- Tonsillitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Fosdenopterin
- Severity Level:
2
- Additional Notes: Insufficient human data available on developmental toxicity risk.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Fosdenopterin
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Molybdenum cofactor deficiency type A | |
| E79.8 | Other disorders of purine and pyrimidine metabolism |
| 0-9 | A-Z |
|---|---|
| E79.8 | Other disorders of purine and pyrimidine metabolism |
Formulary Reference Tool